Literature DB >> 19221494

p53 methylation--the Arg-ument is clear.

Stephen T Durant1, Er Chieh Cho, Nicholas B La Thangue.   

Abstract

p53 Activity is of critical importance in suppressing human cancer formation, highlighted by the fact that the majority of human tumors have defective or inactive p53. In normal cells, p53 is held at low levels in a latent form and, following DNA damage, is stabilized which usually results in apoptosis or cell cycle arrest. Most functions of p53 can be ascribed to its role as a sequence specific transcription factor, and an extensive repertoire of downstream responsive genes have been identified. p53 activity is influenced by post-translational modifications, including phosphorylation and lysine methylation. Most recently, arginine methylation mediated by PRMT5, has been identified as an additional and important p53 modification. DNA damage induced p53 arginine methylation impacts on the biochemical properties and functional outcome of the p53 response.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19221494     DOI: 10.4161/cc.8.6.7850

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  14 in total

1.  Roles of protein arginine methylation in DNA damage signaling pathways is CARM1 a life-or-death decision point?

Authors:  Young-Ho Lee; Michael R Stallcup
Journal:  Cell Cycle       Date:  2011-05-01       Impact factor: 4.534

Review 2.  Role of PRMTs in cancer: Could minor isoforms be leaving a mark?

Authors:  R Mitchell Baldwin; Alan Morettin; Jocelyn Côté
Journal:  World J Biol Chem       Date:  2014-05-26

Review 3.  Protein arginine methyltransferases and cancer.

Authors:  Yanzhong Yang; Mark T Bedford
Journal:  Nat Rev Cancer       Date:  2012-12-13       Impact factor: 60.716

4.  Life or death: p53-induced apoptosis requires DNA binding cooperativity.

Authors:  Katharina Schlereth; Joël P Charles; Anne C Bretz; Thorsten Stiewe
Journal:  Cell Cycle       Date:  2010-10-11       Impact factor: 4.534

5.  Critical role of transmethylation in TLR signaling and systemic lupus erythematosus.

Authors:  Virginie Tardif; Yulia Manenkova; Michael Berger; Kasper Hoebe; Jian-Ping Zuo; Chong Yuan; Dwight H Kono; Argyrios N Theofilopoulos; Brian R Lawson
Journal:  Clin Immunol       Date:  2013-03-05       Impact factor: 3.969

6.  Menin epigenetically represses Hedgehog signaling in MEN1 tumor syndrome.

Authors:  Buddha Gurung; Zijie Feng; Daniel V Iwamoto; Austin Thiel; Guanghui Jin; Chen-Min Fan; Jessica M Y Ng; Tom Curran; Xianxin Hua
Journal:  Cancer Res       Date:  2013-04-11       Impact factor: 12.701

7.  PRMT5 regulates T cell interferon response and is a target for acute graft-versus-host disease.

Authors:  Katiri J Snyder; Nina C Zitzer; Yandi Gao; Hannah K Choe; Natalie E Sell; Lotus Neidemire-Colley; Anora Ignaci; Charuta Kale; Raymond D Devine; Maria G Abad; Maciej Pietrzak; Min Wang; Hong Lin; Yang W Zhang; Gregory K Behbehani; Jane E Jackman; Ramiro Garzon; Kris Vaddi; Robert A Baiocchi; Parvathi Ranganathan
Journal:  JCI Insight       Date:  2020-04-23

8.  Telomerase-independent paths to immortality in predictable cancer subtypes.

Authors:  Stephen T Durant
Journal:  J Cancer       Date:  2012-01-31       Impact factor: 4.207

9.  PRMT5 Selective Inhibitor Enhances Therapeutic Efficacy of Cisplatin in Lung Cancer Cells.

Authors:  Khuloud Bajbouj; Rakhee K Ramakrishnan; Maha Saber-Ayad; Hany A Omar; Narjes Saheb Sharif-Askari; Jasmin Shafarin; Adel B Elmoselhi; Ahmed Ihmaid; Suhib AlHaj Ali; Abdulla Alalool; Reem Abdullah; Qutayba Hamid
Journal:  Int J Mol Sci       Date:  2021-06-07       Impact factor: 5.923

10.  PRMT5 is upregulated in malignant and metastatic melanoma and regulates expression of MITF and p27(Kip1.).

Authors:  Courtney Nicholas; Jennifer Yang; Sara B Peters; Matthew A Bill; Robert A Baiocchi; Fengting Yan; Saïd Sïf; Sookil Tae; Eugenio Gaudio; Xin Wu; Michael R Grever; Gregory S Young; Gregory B Lesinski
Journal:  PLoS One       Date:  2013-09-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.